Skip to main content
Premium Trial:

Request an Annual Quote

SuppreMol to Use Protagen Biomarker Panel

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – German biopharma company SuppreMol will use Protagen's biomarker portfolio to identify markers that may be predictive of which patients may be the best candidates for SuppreMol's lead therapy systemic lupus erythematosus (SLE), the companies said today.

Under the agreement, SuppreMol will use Protagen's UNIarray technology platform in phase IIa clinical trials for a personalized therapy for SLE called SM101.

SuppreMol plans to use the platform to identify autoantibody signatures in the seurm of SLE patients to indicate which of them are most likely to respond favorably to SM101.

"In addition, our findings may allow the classification of patients into subgroups as SLE is a disease with very diverse manifestations," SuppreMol's CEO Peter Buckel said in a statement.

"Both of our companies are convinced that this approach will allow for specific enrollment as well as better stratification of SLE patients, and that it will significantly reduce the development risks of upcoming clinical studies,“ added Stefan Müllner, CEO of Munich-based Protagen.

Financial terms of the agreement were not released.

The Scan

Single-Cell Sequencing Points to Embryo Mosaicism

Mosaicism may affect preimplantation genetic tests for aneuploidy, a single-cell sequencing-based analysis of almost three dozen embryos in PLOS Genetics finds.

Rett Syndrome Mouse Model Study Points to RNA Editing Possibilities

Investigators targeted MECP2 in mutant mouse models of Rett syndrome, showing in PNAS that they could restore its expression and dial down symptoms.

Investigators Find Shared, Distinct Genetic Contributors to Childhood Hodgkin Lymphoma

An association study in JAMA Network Open uncovers risk variants within and beyond the human leukocyte antigen locus.

Transcriptomic, Epigenetic Study Appears to Explain Anti-Viral Effects of TB Vaccine

Researchers report in Science Advances on an interferon signature and long-term shifts in monocyte cell DNA methylation in Bacille Calmette-Guérin-vaccinated infant samples.